In this phase II , randomized , double-blind study , placebo or ixekizumab was administered subcutaneously to @ biologics-naive patients and @ patients with an inadequate response to TNF inhibitors at weeks @ , @ , @ , @ , @ , @ , and @ with concomitant disease-modifying antirheumatic drugs .